These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 38726149)

  • 21. METTL16 Inhibits the Malignant Progression of Epithelial Ovarian Cancer through the lncRNA MALAT1/
    Li C; Liu J; Lyu Y; Ling S; Luo Y
    Anal Cell Pathol (Amst); 2023; 2023():9952234. PubMed ID: 37927399
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CTHRC1 in Ovarian Cancer Promotes M2-Like Polarization of Tumor-Associated Macrophages via Regulation of the STAT6 Signaling Pathway.
    Bai Y; Yin K; Su T; Ji F; Zhang S
    Onco Targets Ther; 2020; 13():5743-5753. PubMed ID: 32606786
    [TBL] [Abstract][Full Text] [Related]  

  • 23. NLRP12 is a prognostic biomarker and correlated with immune infiltrates in epithelial ovarian cancer.
    Ma R; Tang Z; Wang J
    J Gene Med; 2024 Jan; 26(1):e3585. PubMed ID: 37926491
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Upregulation of centrosomal protein 55 is associated with unfavorable prognosis and tumor invasion in epithelial ovarian carcinoma.
    Zhang W; Niu C; He W; Hou T; Sun X; Xu L; Zhang Y
    Tumour Biol; 2016 May; 37(5):6239-54. PubMed ID: 26615423
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization of DOK1, a candidate tumor suppressor gene, in epithelial ovarian cancer.
    Mercier PL; Bachvarova M; Plante M; Gregoire J; Renaud MC; Ghani K; Têtu B; Bairati I; Bachvarov D
    Mol Oncol; 2011 Oct; 5(5):438-53. PubMed ID: 21856257
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Overexpression of kinesin family member 20A is associated with unfavorable clinical outcome and tumor progression in epithelial ovarian cancer.
    Li H; Zhang W; Sun X; Chen J; Li Y; Niu C; Xu B; Zhang Y
    Cancer Manag Res; 2018; 10():3433-3450. PubMed ID: 30254487
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MicroRNA-127-3p acts as a tumor suppressor in epithelial ovarian cancer by regulating the BAG5 gene.
    Bi L; Yang Q; Yuan J; Miao Q; Duan L; Li F; Wang S
    Oncol Rep; 2016 Nov; 36(5):2563-2570. PubMed ID: 27571744
    [TBL] [Abstract][Full Text] [Related]  

  • 28. circDENND4C, a novel serum marker for epithelial ovarian cancer, acts as a tumor suppressor by downregulating miR-200b/c.
    Liu S; Yuan L; Li J; Liu Y; Wang H; Ren X
    Ann Med; 2023 Dec; 55(1):908-919. PubMed ID: 36896567
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Capn4 Enhances Osteopontin Expression through Activation of the Wnt/β-Catenin Pathway to Promote Epithelial Ovarian Carcinoma Metastasis.
    Yang X; Sun J; Xia D; Can X; Liu L; Zhang J; Xu H; Du N; Liu W; Shen F; Zhang Z; Sun Y; Xi X
    Cell Physiol Biochem; 2017; 42(1):185-197. PubMed ID: 28535511
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MicroRNA-130b functions as a tumor suppressor by regulating RUNX3 in epithelial ovarian cancer.
    Paudel D; Zhou W; Ouyang Y; Dong S; Huang Q; Giri R; Wang J; Tong X
    Gene; 2016 Jul; 586(1):48-55. PubMed ID: 27048832
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SLC7A1 Overexpression Is Involved in Energy Metabolism Reprogramming to Induce Tumor Progression in Epithelial Ovarian Cancer and Is Associated with Immune-Infiltrating Cells.
    You S; Zhu X; Yang Y; Du X; Song K; Zheng Q; Zeng P; Yao Q
    J Oncol; 2022; 2022():5864826. PubMed ID: 36131790
    [TBL] [Abstract][Full Text] [Related]  

  • 32. LncRNA MALAT1 Facilitates Ovarian Cancer Progression through Promoting Chemoresistance and Invasiveness in the Tumor Microenvironment.
    Mao TL; Fan MH; Dlamini N; Liu CL
    Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638541
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Expression of p21(WAF1) and its relationship with p53 and PCNA protein in epithelial ovarian cancer].
    Yan XJ; Liang LZ; Li DC; Li JL; Zhang CQ; Yuan SH
    Ai Zheng; 2004 Jan; 23(1):74-80. PubMed ID: 14720380
    [TBL] [Abstract][Full Text] [Related]  

  • 34. M2 Macrophages Infiltrating Epithelial Ovarian Cancer Express MDR1: A Feature That May Account for the Poor Prognosis.
    Badmann S; Heublein S; Mayr D; Reischer A; Liao Y; Kolben T; Beyer S; Hester A; Zeder-Goess C; Burges A; Mahner S; Jeschke U; Trillsch F; Czogalla B
    Cells; 2020 May; 9(5):. PubMed ID: 32429133
    [TBL] [Abstract][Full Text] [Related]  

  • 35. VISTA+/CD8+ status correlates with favorable prognosis in Epithelial ovarian cancer.
    Jlassi A; Manai M; Morjen M; Sahraoui G; Elasmi Allal M; ELBini-Dhouib I; Naija L; Charfi L; Rejaibi R; Ben Ahmed M; Marrakchi N; Srairi-Abid N; Mezlini A; Manai M; Mrad K; Doghri R
    PLoS One; 2023; 18(3):e0278849. PubMed ID: 36952478
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic implications of forkhead box protein O1 (FOXO1) and paired box 3 (PAX3) in epithelial ovarian cancer.
    Han GH; Chay DB; Nam S; Cho H; Chung JY; Kim JH
    BMC Cancer; 2019 Dec; 19(1):1202. PubMed ID: 31823759
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumor Suppressor Effect of RBMS3 in Breast Cancer.
    Wang C; Wu Y; Liu Y; Pan F; Zeng H; Li X; Yu L
    Technol Cancer Res Treat; 2021; 20():15330338211004921. PubMed ID: 33910421
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The correlation of the expressions of WWOX, LGR5 and vasohibin-1 in epithelial ovarian cancer and their clinical significance.
    Yu L; Mao X; Wu S; Zhou L; Song W; Gong X; Wang D
    Int J Clin Exp Pathol; 2019; 12(1):327-336. PubMed ID: 31933749
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Disruption of RBMS3 suppresses PD-L1 and enhances antitumor immune activities and therapeutic effects of auranofin against triple-negative breast cancer.
    Zhou Y; Liang Z; Xia Y; Li S; Liang J; Hu Z; Tang C; Zhao Q; Gong Q; Ouyang Y
    Chem Biol Interact; 2023 Jan; 369():110260. PubMed ID: 36414028
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.